0001209191-20-027487.txt : 20200506
0001209191-20-027487.hdr.sgml : 20200506
20200506163836
ACCESSION NUMBER: 0001209191-20-027487
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200504
FILED AS OF DATE: 20200506
DATE AS OF CHANGE: 20200506
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Arbuckle Stuart A
CENTRAL INDEX KEY: 0001557290
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 20853188
MAIL ADDRESS:
STREET 1: VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-05-04
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001557290
Arbuckle Stuart A
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP, Chief Commercial Officer
Common Stock
2020-05-04
4
M
0
1553
86.52
A
36732
D
Common Stock
2020-05-04
4
S
0
640
259.36
D
36092
D
Common Stock
2020-05-04
4
S
0
320
260.32
D
35772
D
Common Stock
2020-05-04
4
S
0
240
261.34
D
35532
D
Common Stock
2020-05-04
4
S
0
240
262.54
D
35292
D
Common Stock
2020-05-04
4
S
0
113
264.89
D
35179
D
Common Stock
140
I
401(k)
Stock Option (Right to Buy)
86.52
2020-05-04
4
M
0
1553
0.00
D
2027-02-02
Common Stock
1553
4660
D
Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $259.36 (range $258.85 to $259.74).
Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $260.32 (range $259.93 to $260.89).
Open market sales reported on this line occurred at a weighted average price of $261.34 (range $261.01 to $261.73).
Open market sales reported on this line occurred at a weighted average price of $262.54 (range $262.25 to $262.92).
The option vests in 16 quarterly installments from 02/03/2017.
/s/ Sabrina Yohai, Attorney-in-Fact
2020-05-06